All In Biotech

BLA 209196 · Sanofi-Aventis US

Admelog

Insulin Lispro · Intravenous, Subcutaneous, Subcutaneous · Insulin Analog

Last checked: Nov 20, 2026Latest source record: Aug 31, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Dec 11, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

331

68 Phase 3, 9 recruiting

FAERS reports

14,537

8,838 serious, 990 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 3, 2026.

ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )

Mechanism: Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro products. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 11, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
3 products under this application
  • ADMELOG · INSULIN LISPRO 300 UNITS/3ML (100 UNITS/ML) · SOLUTION, INTRAVENOUS, SUBCUTANEOUS · Prescription
  • ADMELOG · INSULIN LISPRO 1000 UNITS/10ML (100 UNITS/ML) · SOLUTION, INTRAVENOUS, SUBCUTANEOUS · Prescription
  • ADMELOG SOLOSTAR · INSULIN LISPRO 300 UNITS/3ML (100 UNITS/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Lispro" as an intervention, any sponsor and status, largest first.

All 331 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased2,450
  • incorrect dose administered887
  • drug ineffective835
  • hypoglycaemia676
  • visual impairment634
  • nausea606
  • dyspnoea575
  • off label use508
  • product dose omission issue507
  • blood glucose decreased477
  • vomiting447
  • diarrhoea436

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200461
200560
200638
200744
200865
200974
201079
201174
2012109
2013131
2014194
2015279
2016292
2017325
2018707
2019926
20201,415
20211,460
20221,568
20231,638
20241,648
20251,955
20261,395

Recalls

2 FDA enforcement reports for this application.

  • Apr 11, 2023 · Class II · Ongoing

    Lack of Assurance of Sterility: Malformed crimped collar seal

  • Jul 5, 2018 · Class II · Ongoing

    Temperature Abuse: Product samples of Admelog may not have been shipped at proper temperature.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Admelog (Insulin Lispro)

2024 spending

$9.8M

Beneficiaries

16,113

46,508 claims

Per beneficiary

$611

$9.78 per unit

View as table
YearSpending
2020$2,461,450
2021$2,224,715
2022$1,595,501
2023$1,393,724
2024$9,842,390

Part D: Admelog Solostar (Insulin Lispro)

2024 spending

$34.0M

Beneficiaries

50,864

152,025 claims

Per beneficiary

$668

$12.32 per unit

View as table
YearSpending
2020$5,785,748
2021$6,137,620
2022$4,563,007
2023$4,074,927
2024$33,991,383

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 354 on PubMed

Sponsor: Sanofi · Also marketed as Admelog Solostar

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.